EFFICACY AND SAFETY OF PENTAVALENT HUMAN-BOVINE REASSORTANT ROTAVIRUS VACCINE WHEN ADMINISTERED WITH GREATER THAN 10 WEEKS BETWEEN DOSESGoveia, Michelle G. MD, MPH; Suprun, Leora MSc; Itzler, Robbin F. PhD; McFetridge, Richard BS; Dallas, Michael J. PhD; Kuter, Barbara J. PhD, MPHPediatric Infectious Disease Journal: March 2010 - Volume 29 - Issue 3 - pp 263-265 doi: 10.1097/INF.0b013e3181be6257 Brief Reports Abstract Author Information The pentavalent human-bovine reassortant rotavirus vaccine is indicated as a 3-dose series with first dose administered orally at 6 to 12 weeks with subsequent doses at 4 to 10 week intervals. In pre-licensure phase III trials, the majority followed this schedule, but there were 2956 instances where infants received a dose of pentavalent human-bovine reassortant rotavirus vaccine/placebo >10 weeks after the previous dose. Among this subset, the efficacy against any severity of disease, the reduction in utilization of healthcare resources and the safety profile after vaccination were comparable with overall results. From the Merck & Co., Inc. West Point, PA. Accepted for publication August 27, 2009. Address for correspondence: Michelle Goveia, MD, MPH, Merck & Co., Inc., PO Box 4, West Point, PA 19486. E-mail: firstname.lastname@example.org. © 2010 Lippincott Williams & Wilkins, Inc.